Compare RCEL & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCEL | NYXH |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.2M | 161.9M |
| IPO Year | 2018 | 2021 |
| Metric | RCEL | NYXH |
|---|---|---|
| Price | $8.12 | $1.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $7.88 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 571.9K | 129.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $71,610,000.00 | N/A |
| Revenue This Year | $17.17 | $213.98 |
| Revenue Next Year | $49.82 | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $3.22 | $1.26 |
| 52 Week High | $8.35 | $6.95 |
| Indicator | RCEL | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 79.06 | 53.71 |
| Support Level | $3.62 | $1.26 |
| Resistance Level | N/A | $1.70 |
| Average True Range (ATR) | 0.51 | 0.06 |
| MACD | 0.37 | 0.04 |
| Stochastic Oscillator | 93.18 | 98.39 |
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.